

# Balaxi Pharmaceuticals Limited

April 02, 2026

To,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

**NSE Symbol: BALAXI**

Dear Sir/Madam,

**Subject: Intimation of Credit Rating Downgrade and Revision in Outlook**

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that CRISIL Ratings Limited has downgraded its rating on the long-term bank facilities of the Company to 'Crisil BBB' while revising the outlook from 'Negative' to 'Stable'.

The details of the Credit Rating downgrade and revision in Outlook is given below:

Name of the Company	Credit Rating Agency	Type of Credit Rating	Prior Rating	Revised Rating
Balaxi Pharmaceuticals Limited	CRISIL Ratings Limited	Long Term	CRISIL BBB+/NEGATIVE	CRISIL BBB/Stable (Outlook revised from 'Negative'; Rating Downgraded)

A copy of press release issued by CRISIL Ratings Limited dated 01<sup>st</sup> April, 2026 covering the rationale for the rating is enclosed.

The aforesaid information is also being hosted on the Company's website at [www.balaxipharma.in](http://www.balaxipharma.in).

This is for your information and records.

Thanking You.

For **Balaxi Pharmaceuticals Limited**

**AMAN  
PUROHIT**

Digitally signed by  
AMAN PUROHIT  
Date: 2026.04.02  
12:03:25 +05'30'

**Aman Purohit**  
**(Company Secretary & Compliance Officer)**  
**ICSI Membership No.: A59345**

Encl: A/a

**Registered Office:**

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096  
CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)

## Rating Rationale

April 01, 2026 | Mumbai

### Balaxi Pharmaceuticals Limited

*Rating downgraded to 'Crisil BBB/Stable'*

#### Rating Action

<b>Total Bank Loan Facilities Rated</b>	<b>Rs.35 Crore</b>
<b>Long Term Rating</b>	<b>Crisil BBB/Stable (Downgraded from 'Crisil BBB+/Negative')</b>

*Note: None of the Directors on Crisil Ratings Limited's Board are members of rating committee and thus do not participate in discussion or assignment of any ratings.*

*The Board of Directors also does not discuss any ratings at its meetings.*

*1 crore = 10 million*

*Refer to Annexure for Details of Instruments & Bank Facilities*

#### Detailed rationale

Crisil Ratings has downgraded its rating on the long-term bank facility of Balaxi Pharmaceuticals Ltd (BPL; part of the Balaxi group) to '**Crisil BBB/Stable**' from '**Crisil BBB+/Negative**'.

The rating downgrade reflects continuing pressure on the profitability of the company in the ongoing fiscal with significant increase in sales and marketing expenditure over the medium term. The company is actively investing in promotional and marketing expenditure to enter and penetrate a new segment (institutional sales) which is impacting profitability. Revenue is expected to be Rs 280 crore, similar to fiscal 2025. The operating margin is expected to be lower at 5% in comparison to 12% in fiscal 2025. Furthermore, because of the shift in business model, the working capital cycle is also expected to remain stretched over the medium term.

The rating continues to reflect BPL's established market position in Angola and Latin America, recovery in revenue performance, extensive experience of the key promoter in the pharmaceuticals industry and healthy financial risk profile. These strengths are partially offset by large working capital requirement, moderation in profitability and revenue concentration risks.

#### Analytical approach

Crisil Ratings has combined the business and financial risk profiles of BPL with its wholly owned subsidiary and step-down subsidiaries. This is because all these entities, collectively referred to as the Balaxi group, are in the same business, have common promoters and strong business and financial links.

*Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.*

#### Key rating drivers - Strengths

##### **Established market position in Angola and Latin America:**

The group has an established market position in countries such as Angola, Dominican Republic and Guatemala. Benefits from the recognition of products and brands by doctors, pharmacists and healthcare professionals across these markets should continue over the medium term.

##### **Recovery in revenue performance:**

The company has managed to improve its revenue performance in fiscal 2025 with reported revenue of Rs 294 crore as against Rs 241 crore in fiscal 2024. The recovery has been supported by better demand scenario in the key market of Angola and incremental contribution from the institutional business. The company is shifting its business model towards institutional sales and, hence, the revenue will remain at similar levels as that of fiscal 2025 due to time taken to capture a new market. The manufacturing facility in India is expected to commence commercial operations in fiscal 2027 and is currently undergoing validations and other approvals. Though the facility in India is more from a backward integration point of view, the company will benefit in terms of operating efficiency and increased revenue contribution.

##### **Extensive experience of the key promoter:**

The key promoter, Ashish Maheshwari, has experience of around two decades in the pharmaceuticals industry; his strong understanding of market dynamics and healthy relationships with suppliers and customers should continue to support the business. The company will continue to benefit from the experience and expertise of its management team and leverage its customer relationships.

**Healthy financial risk profile:**

BPL's financial risk profile is supported by comfortable network, healthy capital structure and robust debt protection metrics. The capital structure is strong, as reflected in gearing and total outside liabilities to tangible network (TOLTNW) ratio of 0.25 time and 0.37 time, respectively, as on March 31, 2025, while the network is comfortable at Rs 204.9 crore. The debt protection metrics are expected to moderate in the ongoing fiscal, but will recover in fiscal 2027.

The financial risk profile is expected to remain healthy, with no debt-funded capex in the pipeline.

**Key rating drivers - Weaknesses****Moderation in profitability:**

The operating profitability will remain impacted over the medium term on account of the shift in business mix to institutional sales from retail sales. The company is investing in promotional and marketing expenditure to enter and penetrate the new segment, which has impacted profitability. Gross profit margin continues to be at similar healthy levels, but the impact on net margin is on account of the incremental marketing and business expenditure to attract and add institutional customers. The business expenditure is expected to continue to be higher in the next one year and, hence, profitability is expected to be subdued. The ability of the company to improve profitability will remain monitorable.

**Working capital-intensive operations:**

Operations are working capital intensive as reflected in gross current assets (GCAs) of 295 days as on March 31, 2025. Due to the stock and sell model of the business, inventory will remain higher at around 120 days while debtors increased on account of shift in the business model. The collection cycle for the institutional segment remained higher at 180–240 days, which has stretched the receivables to 138 days as on March 31, 2025.

**Revenue concentration risks:**

Given that more than 50% of the revenue comes from Angola, the company remains vulnerable to economic uncertainties in the region and volatility in currency rates.

**Liquidity Adequate**

Bank limit utilisation was moderate at 83% on average for the 12 months through January 2026.

Despite reduction in net cash accrual to Rs 4 crore expected in fiscal 2026, the debt obligation was less than Rs 2 crore. The current ratio was healthy at 4.52 times as on March 31, 2025. Low gearing and moderate network support financial flexibility and provide the financial cushion required in case of any adverse conditions or downturn in the business.

**Outlook Stable**

The profitability metrics and working capital cycle are expected to improve, especially in the Angolan market.

**Rating sensitivity factors****Upward factors:**

- Improvement in the business performance with revenue or strong margin resulting in net cash accrual of above Rs 25 crore
- Sustenance of the financial risk profile at healthy levels

**Downward factors:**

- Continuance of weak profitability metrics in the upcoming fiscal with operating margin at less than 5%
- Any weakening of the financial risk profile or impact on liquidity on account of higher working capital requirement

**About the group**

The Balaxi group is an IPR-based pharmaceuticals player supplying to Angola and Latin America under the brand, Balaxi. The group is also involved in branding and selling pharmaceutical products and construction materials. It is promoted by Ashish Maheshwari and his family members.

During the nine months through December 2025, the group reported consolidated revenue and net profit of Rs 199.45 crore and Rs 0.80 crore, respectively, as against Rs 216.29 crore and Rs 16.43 crore, respectively, in the corresponding period of the previous fiscal.

**Key financial indicators**

As on/for the period ended March 31	Consolidated	2025	2024
Operating income	Rs crore	294.92	241.93
Reported profit after tax (PAT)	Rs crore	25.07	-2.39
PAT margin	%	8.5	-0.99
Adjusted debt/adjusted network	Times	0.25	0.10
Interest coverage	Times	8.64	16.35

**Any other information:** Not applicable

**Note on complexity levels of the rated instrument:**

Crisil Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

Crisil Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the Crisil Ratings` complexity levels please visit [www.crisilratings.com](http://www.crisilratings.com). Users may also call the Customer Service Helpdesk with queries on specific instruments.

**Annexure - Details of Instrument(s)**

ISIN	Name Of Instrument	Date Of Allotment	Coupon Rate (%)	Maturity Date	Issue Size (Rs. Crore)	Complexity Levels	Rating Outstanding with Outlook
NA	Working Capital Facility	NA	NA	NA	35.00	NA	Crisil BBB/Stable

**Annexure – List of entities consolidated**

Names of Entities Consolidated	Extent of Consolidation	Rationale for Consolidation
Balaxi Healthcare Guatemala S. A.	Full	Step down subsidiary
Balaxi Healthcare Dominicana S.R.L.	Full	Step down subsidiary
Balaxi Helthcare Angola (SU) LDA	Full	Step down subsidiary
Balaxi Pharmaceuticals Ltd	Full	Parent company
Balaxi Healthcare Angola LDA	Full	Step down subsidiary
Balaxi Healthcare Honduras	Full	Step down subsidiary
Balaxi Healthcare Chile	Full	Step down subsidiary
Balaxi Healthcare Nicaragua	Full	Step down subsidiary

**Annexure - Rating History for last 3 Years**

Instrument	Type	Current		2026 (History)		2025		2024		2023		Start of 2023
		Outstanding Amount	Rating	Date	Rating	Date	Rating	Date	Rating	Date	Rating	Rating
Fund Based Facilities	LT	35.0	Crisil BBB/Stable		--	13-11-25	Crisil BBB+/Negative	05-11-24	Crisil BBB+/Stable	14-08-23	Crisil BBB+/Negative	Crisil BBB+/Stable

All amounts are in Rs.Cr.

**Annexure - Details of Bank Lenders & Facilities**

Facility	Amount (Rs.Crore)	Name of Lender	Rating
Working Capital Facility	35	YES Bank Limited	Crisil BBB/Stable

**Criteria Details**

<b>Links to related criteria</b>
<a href="#">Basics of Ratings (including default recognition, assessing information adequacy)</a>
<a href="#">Criteria for consolidation</a>
<a href="#">Criteria for manufacturing, trading and corporate services sector (including approach for financial ratios)</a>

Media Relations	Analytical Contacts	Customer Service Helpdesk
<p><b>Ramkumar Uppara</b> Media Relations <b>Crisil Limited</b> M: +91 98201 77907 B: +91 22 6137 3000 <a href="mailto:ramkumar.uppara@crisil.com">ramkumar.uppara@crisil.com</a></p> <p><b>Kartik Behl</b> Media Relations <b>Crisil Limited</b> M: +91 90043 33899 B: +91 22 6137 3000 <a href="mailto:kartik.behl@crisil.com">kartik.behl@crisil.com</a></p> <p><b>Divya Pillai</b> Media Relations <b>Crisil Limited</b> M: +91 86573 53090 B: +91 22 6137 3000 <a href="mailto:divya.pillai1@ext-crisil.com">divya.pillai1@ext-crisil.com</a></p>	<p>Himank Sharma Director <b>Crisil Ratings Limited</b> D: +91 124 672 2152 <a href="mailto:himank.sharma@crisil.com">himank.sharma@crisil.com</a></p> <p>Nagarjun Alaparathi Associate Director <b>Crisil Ratings Limited</b> B: +91 40 4032 8200 <a href="mailto:nagarjun.alaparathi@crisil.com">nagarjun.alaparathi@crisil.com</a></p> <p>Akhil Thomas Manager <b>Crisil Ratings Limited</b> B: +91 40 4032 8200 <a href="mailto:akhil.thomas@crisil.com">akhil.thomas@crisil.com</a></p> <p><b>For Analytical queries</b> Toll Free Number: 1800 266 6550 <a href="mailto:ratingsinvestordesk@crisil.com">ratingsinvestordesk@crisil.com</a></p>	<p>Timings: 10.00 am to 7.00 pm Toll Free Number: 1800 267 3850</p> <p>For a copy of Rationales / Rating Reports: <a href="mailto:CRISILratingdesk@crisil.com">CRISILratingdesk@crisil.com</a></p>



**Note for Media:**

This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to Crisil Ratings. However, Crisil Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.

**About Crisil Ratings Limited (A subsidiary of Crisil Limited, an S&P Global Company)**

Crisil Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).

Crisil Ratings Limited ('Crisil Ratings') is a wholly-owned subsidiary of Crisil Limited ('Crisil'). Crisil Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").

For more information, visit [www.crisilratings.com](http://www.crisilratings.com)

**About Crisil Limited**

Crisil is a leading, agile and innovative global analytics company driven by its mission of making markets function better.

It is India's foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit [www.crisil.com](http://www.crisil.com)

Connect with us: [TWITTER](#) | [LINKEDIN](#) | [YOUTUBE](#) | [FACEBOOK](#)

**CRISIL PRIVACY NOTICE**

Crisil respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from Crisil. For further information on Crisil's privacy policy please visit [www.crisil.com](http://www.crisil.com).

**DISCLAIMER**

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') provided by Crisil Ratings Limited ('Crisil Ratings'). For the avoidance of doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for use only within the jurisdiction of India. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as Crisil Ratings provision or intention to provide any services in jurisdictions where Crisil Ratings does not have the necessary licenses and/or registration to carry out its business activities. Access or use of this report does not create a client relationship between Crisil Ratings and the user.

The report is a statement of opinion as on the date it is expressed, and it is not intended to and does not constitute investment advice within meaning of any laws or regulations (including US laws and regulations). The report is not an offer to sell or an offer to purchase or subscribe to any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way.

Crisil Ratings and its associates do not act as a fiduciary. The report is based on the information believed to be reliable as of the date it is published, Crisil Ratings does not perform an audit or undertake due diligence or independent verification of any information it receives and/or relies on for preparation of the report. THE REPORT IS PROVIDED ON "AS IS" BASIS. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, CRISIL RATINGS DISCLAIMS WARRANTY OF ANY KIND,

EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE. In no event shall Crisil Ratings, its associates, third-party providers, as well as their directors, officers, shareholders, employees or agents be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

The report is confidential information of Crisil Ratings and Crisil Ratings reserves all rights, titles and interest in the rating report. The report shall not be altered, disseminated, distributed, redistributed, licensed, sub-licensed, sold, assigned or published any content thereof or offer access to any third party without prior written consent of Crisil Ratings.

Crisil Ratings or its associates may have other commercial transactions with the entity to which the report pertains or its associates. Ratings are subject to revision or withdrawal at any time by Crisil Ratings. Crisil Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

Crisil Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For more detail, please refer to: <https://www.crisilratings.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html>. Public ratings and analysis by Crisil Ratings, as are required to be disclosed under the Securities and Exchange Board of India regulations (and other applicable regulations, if any), are made available on its websites, [www.crisilratings.com](http://www.crisilratings.com) and <https://www.ratingsanalytica.com> (free of charge). Crisil Ratings shall not have the obligation to update the information in the Crisil Ratings report following its publication although Crisil Ratings may disseminate its opinion and/or analysis. Reports with more detail and additional information may be available for subscription at a fee. Rating criteria by Crisil Ratings are available on the Crisil Ratings website, [www.crisilratings.com](http://www.crisilratings.com). For the latest rating information on any company rated by Crisil Ratings, you may contact the Crisil Ratings desk at [crisilratingdesk@crisil.com](mailto:crisilratingdesk@crisil.com), or at (0091) 1800 267 3850.

Crisil Ratings shall have no liability, whatsoever, with respect to any copies, modifications, derivative works, compilations or extractions of any part of this [report/ work products], by any person, including by use of any generative artificial intelligence or other artificial intelligence and machine learning models, algorithms, software, or other tools. Crisil Ratings takes no responsibility for such unauthorized copies, modifications, derivative works, compilations or extractions of its [report/ work products] and shall not be held liable for any errors, omissions of inaccuracies in such copies, modifications, derivative works, compilations or extractions. Such acts will also be in breach of Crisil Ratings' intellectual property rights or contrary to the laws of India and Crisil Ratings shall have the right to take appropriate actions, including legal actions against any such breach.

Crisil Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on Crisil Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: <https://www.crisilratings.com/en/home/our-business/ratings/credit-ratings-scale.html>